One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Can Serum Proteomic Profiling Annunciate Individual Disease Progression in Newly Diagnosed Inflammatory Bowel Disease Patients?
Raja Atreya, Markus F Neurath
doi : 10.1093/ecco-jcc/jjab009
Volume 15, Issue 5, May 2021, Pages 697–698
The awareness that ongoing mucosal inflammation leads to long-term sequelae and poor outcomes in inflammatory bowel disease [IBD] patients has led to a paradigm shift in in our therapeutic algorithms, as early intervention with immunosuppressant and biologic therapy is believed to prevent disease progression and avoid complications.1 However, rational therapeutic management of newly diagnosed IBD patients has been hampered by the clinical heterogeneity in IBD and the ongoing conundrum: which treatment approach to employ in the individual patient. The most important parameter to guide our therapeutic decisions is the prognosis of the assumable disease course of the patient. Patients who are predisposed to...
Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease
R Kalla, A T Adams, D Bergemalm, S Vatn, N A Kennedy ...
doi : 10.1093/ecco-jcc/jjaa230
Volume 15, Issue 5, May 2021, Pages 699–708
Success in personalized medicine in complex disease is critically dependent on biomarker discovery. We profiled serum proteins using a novel proximity extension assay [PEA] to identify diagnostic and prognostic biomarkers in inflammatory bowel disease [IBD].
Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model
Remi Mahmoud, Chris van Lieshout, Geert W J Frederix, Bindia Jharap, Bas Oldenburg ...
doi : 10.1093/ecco-jcc/jjaa219
Volume 15, Issue 5, May 2021, Pages 709–718
Anti-tumour necrosis factor alpha [anti-TNF] treatment accounts for 31% of health care expenditures associated with ulcerative colitis [UC]. Withdrawal of anti-TNF in patients with UC in remission may decrease side effects and infections, while promoting cost containment. Approximately 36% of patients relapse within 12–24 months of anti-TNF withdrawal, but reintroduction of treatment is successful in 80% of patients. We aimed to evaluate the cost-effectiveness of continuation versus withdrawal of anti-TNF in patients with UC in remission.
The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Min-A Kim, Young-Han Kim, Jaeyoung Chun, Hye Sun Lee, Soo Jung Park ...
doi : 10.1093/ecco-jcc/jjaa225
Volume 15, Issue 5, May 2021, Pages 719–732
Robust evidence regarding the impact of disease activity on pregnancy outcomes in women with inflammatory bowel disease [IBD] is crucial for both clinicians and patients in preparing a birth plan. We sought to perform a systematic review and meta-analysis to assess the pooled influences of disease activity on pregnancy outcomes in women with IBD.
Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis
Brigida Barberio, Christopher J Black, Edoardo V Savarino, Alexander C Ford
doi : 10.1093/ecco-jcc/jjaa226
Volume 15, Issue 5, May 2021, Pages 733–741
Despite randomized controlled trials [RCTs] and trial-based meta-analyses, the optimal rescue therapy for patients with acute glucorticosteroid-refractory ulcerative colitis [UC], to avoid colectomy and improve long-term outcomes, remains unclear. We conducted a network meta-analysis examining this issue.
Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study
My-Linh Tran-Minh, Jean-Marc Gornet, Marianne Maillet, Pascal Houze, Marion Simon ...
doi : 10.1093/ecco-jcc/jjaa231
Volume 15, Issue 5, May 2021, Pages 742–748
Hydrocortisone premedication reduces the risk of antibodies to infliximab [ATIs] formation in patients receiving infliximab [IFX] therapy for inflammatory bowel disease [IBD].
Automated Detection of Crohn’s Disease Intestinal Strictures on Capsule Endoscopy Images Using Deep Neural Networks
Eyal Klang, Ana Grinman, Shelly Soffer, Reuma Margalit Yehuda, Oranit Barzilay ...
doi : 10.1093/ecco-jcc/jjaa234
Volume 15, Issue 5, May 2021, Pages 749–756
Passable intestinal strictures are frequently detected on capsule endoscopy [CE]. Such strictures are a major component of inflammatory scores. Deep neural network technology for CE is emerging. However, the ability of deep neural networks to identify intestinal strictures on CE images of Crohn’s disease [CD] patients has not yet been evaluated.
Association Between Statin Use and Inflammatory Bowel Diseases: Results from a Swedish, Nationwide, Population-based Case-control Study
Paul Lochhead, Hamed Khalili, Michael C Sachs, Andrew T Chan, Ola Olén ...
doi : 10.1093/ecco-jcc/jjaa235
Volume 15, Issue 5, May 2021, Pages 757–765
In addition to their potent lipid-lowering action, statins may modulate inflammation. However, data on statin use and the risk of inflammatory bowel diseases [IBD] have been inconsistent.
The IBD-disk Is a Reliable Tool to Assess the Daily-life Burden of Patients with Inflammatory Bowel Disease
Sara Tadbiri, Maria Nachury, Yoram Bouhnik, Melanie Serrero, Xavier Hébuterne ...
doi : 10.1093/ecco-jcc/jjaa244
Volume 15, Issue 5, May 2021, Pages 766–773
The inflammatory bowel disease [IBD]-disk is a 10-item self-questionnaire that is used to assess IBD-related disability. The aim of the present study was to evaluate this tool in the assessment of IBD daily-life burden.
Ileal Transcriptomic Analysis in Paediatric Crohn’s Disease Reveals IL17- and NOD-signalling Expression Signatures in Treatment-naïve Patients and Identifies Epithelial Cells Driving Differentially Expressed Genes
James J Ashton, Konstantinos Boukas, James Davies, Imogen S Stafford, Andres F Vallejo ...
doi : 10.1093/ecco-jcc/jjaa236
Volume 15, Issue 5, May 2021, Pages 774–786
Crohn’s disease [CD] arises through host-environment interaction. Abnormal gene expression results from disturbed pathway activation or response to bacteria. We aimed to determine activated pathways and driving cell types in paediatric CD.
Increased Mucosal Thrombin is Associated with Crohn’s Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation
Jean-Paul Motta, Simone Palese, Carmine Giorgio, Kevin Chapman, Alexandre Denadai-Souza ...
doi : 10.1093/ecco-jcc/jjaa229
Volume 15, Issue 5, May 2021, Pages 787–799
Thrombin levels in the colon of Crohn’s disease patients have recently been found to be elevated 100-fold compared with healthy controls. Our aim was to determine whether and how dysregulated thrombin activity could contribute to local tissue malfunctions associated with Crohn’s disease.
The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn’s Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation
Andrew Nelson, Christopher J Stewart, Nicholas A Kennedy, John K Lodge, Mark Tremelling ...
doi : 10.1093/ecco-jcc/jjaa220
Volume 15, Issue 5, May 2021, Pages 800–812
Historical and emerging data implicate fungi in Crohn’s disease [CD] pathogenesis. However, a causal link between mycobiota, dysregulated immunity, and any impact of NOD2 variants remains elusive. This study aims to evaluate associations between NOD2 variants and faecal mycobiota in CD patients and non-CD subjects.
Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review
Kate Gallagher, Alexandra Catesson, Julian L Griffin, Elaine Holmes, Horace R T Williams
doi : 10.1093/ecco-jcc/jjaa227
Volume 15, Issue 5, May 2021, Pages 813–826
The inflammatory bowel diseases [IBD], Crohn’s disease and ulcerative colitis, are chronic, idiopathic gastrointestinal diseases. Although their precise aetiology is unknown, it is thought to involve a complex interaction between genetic predisposition and an abnormal host immune response to environmental exposures, probably microbial. Microbial dysbiosis has frequently been documented in IBD. Metabolomics [the study of small molecular intermediates and end products of metabolism in biological samples] provides a unique opportunity to characterize disease-associated metabolic changes and may be of particular use in quantifying gut microbial metabolism. Numerous metabolomic studies have been undertaken in IBD populations, identifying consistent alterations in a range of molecules across several biological matrices. This systematic review aims to summarize these findings.
Characteristics of Lymphoma in Patients with Inflammatory Bowel Disease: A Systematic Review
Marie Muller, Julien Broséus, Pierre Feugier, Catherine Thieblemont, Laurent Beaugerie ...
doi : 10.1093/ecco-jcc/jjaa193
Volume 15, Issue 5, May 2021, Pages 827–839
Lymphoma is a dreaded complication of inflammatory bowel diseases [IBD]. Knowledge about lymphoma in patients with IBD is limited to epidemiological data and the description of risk factors. We performed a systematic review to describe the clinical characteristics and prognosis of lymphoma in patients with IBD.
TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review
Marie Muller, Ferdinando D’Amico, Stefanos Bonovas, Silvio Danese, Laurent Peyrin-Biroulet
doi : 10.1093/ecco-jcc/jjaa186
Volume 15, Issue 5, May 2021, Pages 840–859
The association between tumour necrosis factor inhibitors [TNFi] and malignancy in patients with inflammatory bowel disease [IBD] is not well understood. Our aim was to systematically evaluate the impact of TNFi use on risk of malignancy in IBD patients in daily clinical practice.
Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry
Manasi Agrawal, Erica J Brenner, Xian Zhang, Jean-Frederic Colombel, Michael D Kappelman ...
doi : 10.1093/ecco-jcc/jjaa243
Volume 15, Issue 5, May 2021, Pages 860–863
We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry.
Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy
Roberto Berte’, Stefano Mazza, Marta Rachele Stefanucci, Daniele Noviello, Stefania Costa ...
doi : 10.1093/ecco-jcc/jjaa237
Volume 15, Issue 5, May 2021, Pages 864–868
A similar course of COVID-19 in patients with inflammatory bowel diseases [IBD] and in the general population has been reported. However, disease prevalence in IBD patients is presently unknown. In this prospective observational study, we aimed at determining SARS-CoV2 infection prevalence in IBD patients treated with biologic therapy.
Remote Monitoring of Inflammatory Bowel Disease: What Kind of Patient-Reported Questionnaires Should We Use?
Ashkan Rezazadeh Ardabili, Evelien M B Hendrix, Marie J Pierik
doi : 10.1093/ecco-jcc/jjaa228
Volume 15, Issue 5, May 2021, Pages 869–870
We read with interest the review by Van Andel et al. regarding the content validity of inflammatory bowel disease [IBD]-specific patient-reported outcome measures [PROMs] using the COnsensus-based Standards for the selection of health Measurement INstruments [COSMIN] methodology.1 We compliment the authors for this extensive assessment and agree that adequately validated PROMs that measure the patient perspective are essential to guarantee high-quality care. However, we believe that one should differentiate between PROMs reflecting the patient perspective and patient-reported questionnaires quantifying outcomes prioritized by healthcare professionals.
Rechallenge with Subcutaneous Ustekinumab After Hypersensitivity Reaction to Intravenous Ustekinumab
Sheena Crosby, Michael J Schuh, Francis A Farraye
doi : 10.1093/ecco-jcc/jjaa202
Volume 15, Issue 5, May 2021, Page 871
COVID-19 in the IBD Population: The Need for Correct Nomenclature
Ashkan Rezazadeh Ardabili, Rob H Creemers, Adriaan A van Bodegraven
doi : 10.1093/ecco-jcc/jjaa222
Volume 15, Issue 5, May 2021, Pages 872–873
We read with great interest the article by Attauabi et al. in which they describe COVID-19 prevalence and outcomes in IBD patients in a Danish population-based cohort.1 We commend the authors for establishing a population-based setting, as this adds to a better understanding of potential risk factors and implications of COVID-19 for the IBD population.
Corrigendum to: Inhibition of Histone Deacetylation by MS-275 Alleviates Colitis by Activating the Vitamin D Receptor
Chunxiao Li, Yi Chen, Huatuo Zhu, Xiuming Zhang, Lu Han ...
doi : 10.1093/ecco-jcc/jjaa209
Volume 15, Issue 5, May 2021, Page 874
Erratum to: A Diversified Dietary Pattern Is Associated With a Balanced Gut Microbial Composition of Faecalibacterium and Escherichia/Shigella in Patients With Crohn’s Disease in Remission
Zhengxiao Zhang, Lorian Taylor, Nusrat Shommu, Subrata Ghosh, Raylene Reimer ...
doi : 10.1093/ecco-jcc/jjaa212
Volume 15, Issue 5, May 2021, Page 875
